Alto Neuroscience, Inc.
NYSE:ANROBiotechnology
+$0.40 today
- Market cap
- $1.04B
- Beta
- 1.25
- P/E (TTM)
- -9.8
- EPS (TTM)
- -$2.26
Volume 0.99M
Average 0.34M
ANRO Weighted Avg Shares
Average number of basic shares outstanding during the period, used to calculate basic EPS.
Alto Neuroscience, Inc.NYSE: ANRO
Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026
Weighted avg shares growth accelerates
Q1 FY2026 weighted avg shares of 32.89M shares rose 21.6% year over year, ahead of the +10.2% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 3.0% from the prior quarter. Over 3 fiscal years it compounded at +4.1% a year.
Context
- Weighted avg shares increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +21.6% holds above the trailing-twelve-month pace of +10.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares history
Shares · from the income statement
- Latest · FY2025
- 28.85M USD
- Year-over-year change
- +17.3%
- 4-year CAGR
- +3.1%
| Period | Period end | Weighted Avg Shares | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 28.85M | +17.3% |
| FY2024 | 2024-12-31 | 24.6M | -8.5% |
| FY2023 | 2023-12-31 | 26.88M | +5.1% |
| FY2022 | 2022-12-31 | 25.57M | +0.0% |
| FY2021 | 2021-12-31 | 25.57M | — |
Weighted Avg Shares vs competitors
How ANRO compares with its peers on the latest reported figures
- ANRO's LTM Mar 2026 weighted avg shares of 29.75M shares is the 9th highest of the 11 companies compared; the peer median is 69.17M shares.
- Its year-over-year change of +10.2% is the 4th highest of 10, against a peer median of +2.9%.
- Over three fiscal years its annual growth of +4.1% compares with a peer median of +7.3%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | 100.38M | +2.9% | +30.1% | |
| LTM Mar 2026 | 99.9M | -2.5% | +6.4% | |
| LTM Mar 2026 | 88.66M | -7.8% | +3.7% | |
| LTM Mar 2026 | 84.87M | +21.1% | +8.2% | |
| LTM Mar 2026 | 78.18M | +22.5% | +41.5% | |
| LTM Mar 2026 | 60.16M | +1.0% | +0.9% | |
| LTM Mar 2026 | 31.49M | — | +63.9% | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | 30.55M | +18.4% | +3.3% |
| LTM Mar 2026 | 29.75M | +10.2% | +4.1% | |
| LTM Mar 2026 | 20.78M | +1.0% | +1.1% | |
| LTM Mar 2026 | 9.94M | +8.7% | +232.8% | |
| Peer median (excluding ANRO) | 69.17M | +2.9% | +7.3% | |
Competitors are the stored peer set for ANRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 210K | 0 | 0 | 0 | 0 |
| Cost of Revenue | 145K | 342K | 0 | 502K | 661K |
| Gross Profit | 65K | (342K) | 0 | (502K) | (661K) |
| Gross Margin | 31.0% | — | — | — | — |
| Research & Development | 8.37M | 23.69M | 30.29M | 47M | 45.62M |
| Selling, General & Admin | 3.75M | 5.16M | 7.52M | 21.61M | 20.75M |
| Operating Expenses | 12.12M | 28.85M | 37.81M | 68.11M | 65.7M |
| Depreciation & Amortization | 145K | 342K | 373K | 502K | 661K |
| EBITDA | (9.04M) | (27.37M) | (34.56M) | (62.3M) | (60.11M) |
| EBITDA Margin | -4305.7% | — | — | — | — |
| Operating Income | (12.06M) | (29.19M) | (37.81M) | (68.61M) | (66.36M) |
| Operating Margin | -5741.0% | — | — | — | — |
| Interest Income | 2K | 114K | 2.35M | 8.85M | 6.6M |
| Interest Expense | 0 | 0 | 1.37M | (1.38M) | 2.47M |
| Other Income / Expenses | 2.87M | 1.48M | 1.5M | 7.18M | 3.13M |
| Income Before Tax | (9.19M) | (27.71M) | (36.31M) | (61.43M) | (63.24M) |
| Pre-Tax Margin | -4374.8% | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (9.19M) | (27.71M) | (36.31M) | (61.43M) | (63.24M) |
| Net Margin | -4374.8% | — | — | — | — |
| EPS (Basic) | (0.36) | (1.08) | (1.35) | (2.50) | (2.19) |
| EPS (Diluted) | (0.36) | (1.08) | (1.35) | (2.50) | (2.19) |
| Weighted Avg Shares | 25.57M | 25.57M | 26.88M | 24.6M | 28.85M |
| Weighted Avg Shares (Diluted) | 25.57M | 25.57M | 26.88M | 24.6M | 28.85M |
Alto Neuroscience, Inc.
NYSE:ANRO
Intrinsic Alpha fair value
Locked
Current Price
$25.91
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.